Sam Chun Dang Pharm disclosed on Monday that it has secured a U.S. licensing agreement for generic versions of the oral diabetes medication Rybelsus and the oral obesity treatment Wegovy Oral (semaglutide).
The deal, targeting the U.S. market, involves an undisclosed partner. Valued at 100 million USD, the contract stipulates payments based on milestone achievements.
The agreement covers generic versions of Rybelsus (1.6 mg, 3 mg, 4 mg, 7 mg, 9 mg, 14 mg) and Wegovy Oral (1.6 mg, 4 mg, 9 mg, 25 mg).
The contract term is set for 10 years following product launch, with automatic two-year extensions contingent on meeting sales targets. The profit-sharing structure allocates 90% of operating profits to the partner and 10% to Sam Chun Dang Pharm.